A body of research has proved that patients who receive anti-inflammatory therapy have a lower risk of lung cancer and lung cancer mortality. Now, a new study presented at the European Society of Cardiology meeting has found that a commonly prescribed anti-inflammatory drug has the same effect…
“As an inflammatory biologist and cardiologist, my primary interest is in heart disease, but my colleagues and I were aware of experimental research indicating a connection between cancer and inflammation,” said Paul M Ridker, director of the Center for Cardiovascular Disease Prevention at Brigham and Women's Hospital and one of the presenters of the Canakinumab Anti-inflammatory Thrombosis Study (CANTOS).
Read on for the full story…
The primary goal of CANTOS was to test if anti-inflammatory therapy reduces risk of cardiovascular events
CANTOS is a randomised, double-blinded trial of canakinumab, an anti-inflammatory drug used to treat arthritis
. The primary goal of the study was to test if the drug reduces risk of cardiovascular events such as stroke, heart attack and cardiovascular death.
More than 10,000 people with a history of heart attacks took part in this study. However, none of these people had been diagnosed with cancer
Did you know, cannabis can be GOOD for your health?
No. I’m not suggesting you start smoking dagga!
I want to introduce you to the powerful healing properties of a very special oil, which although it does come from the cannabis plant, is completely legal and will NOT make you high. Instead, research shows this special oil can help treat everything from cancer, to seizures, to heart conditions, to anxiety and various skin conditions.
Curious? Click here to find out about nature’s best-kept secret for yourself.
Canakinumab – a common arthritis drug – also curbs lung cancer risk, according to a new study
To reach these findings, the researchers conducted a study in which they gave participants either 50 mg, 150 mg or 300 mg of canakinumab, or a placebo. They injected the drugs into the people subcutaneously every three months and followed them for up to five and a half years.
The researchers observed a marked reduction in rates of cancer death among those who received canakinumab, especially in death due to lung cancer. They also noticed a lower incidence of lung cancer among those who received the anti-inflammatory drug.
Furthermore, the researchers observed that the people who received the highest dose of Canakinumab had approximately half the rate of total cancer deaths and one-quarter the rate of fatal lung cancer compared with those who received the placebo.
Note: 5 of 1 vote